Response to first-line chemotherapy regimen to predict efficacy of nivolumab in lung cancer.

3026Background: Nivolumab is a monoclonal antibody, targeting PD-1 receptor and demonstrating durable clinical benefit in 20% of metastatic NSCLC patients in second and further treatment lines. The...